Standardized symptomatic treatment versus penicillin as initial therapy for streptococcal pharyngitis

Area of Science:

• Infectious Diseases
• Pharmacology
• Clinical Medicine

Background:

• Pharyngitis is commonly caused by group A beta-hemolytic streptococcus (GABHS).
• Symptomatic relief for GABHS pharyngitis often includes anti-inflammatory drugs.
• The efficacy of adjunctive penicillin for acute symptom relief is debated.

Purpose of the Study:

• To compare penicillin plus symptomatic therapy versus symptomatic therapy alone for GABHS pharyngitis.
• To evaluate the impact of penicillin on acute discomforts associated with GABHS pharyngitis.

Main Methods:

• Multicenter, double-blind, randomized, placebo-controlled trial.
• 178 patients (aged 4-29 years) with GABHS pharyngitis received symptomatic therapy with either penicillin or placebo for 48 hours.
• Clinical assessments included symptom evaluation and throat cultures.

Main Results:

• Penicillin showed a 20% improvement in sore throat relief at 48 hours for patients with GABHS (p = 0.01).
• No significant differences were observed in fever, malaise, odynophagia, exudate, adenitis, or overall pharyngitis severity.
• Benefit was more pronounced in patients with severe pharyngitis and GABHS (p = 0.05).

Conclusions:

• Adjunctive penicillin offers limited additional benefit for symptomatic relief of GABHS pharyngitis beyond standard care.
• The routine early prescription of penicillin for acute symptom management in GABHS pharyngitis is not strongly supported by these findings.
• Further research may be needed to identify specific patient subgroups that could benefit from penicillin therapy.